Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US
Findings support relugolix use as an oral treatment due to its favorable persistence and long-term adherence profiles.
Authors
- Jason Hafron (ORCID: https://orcid.org/0000-0003-0866-797X)
- Frédéric Kinkead
- Scott C. Flanders
- Michael J. Ryan (ORCID: https://orcid.org/0000-0002-5679-6031)
- Rana R. McKay (ORCID: https://orcid.org/0000-0002-0581-7963)
- Hela Romdhani (ORCID: https://orcid.org/0000-0001-5219-2612)
- Agnes Hong
Institutions
- Pfizer (United States) (US)
- UC San Diego Health System (US)
- University of California San Diego (US)
- Michigan Institute of Urology (US)
- Sumitomo Dainippon Pharma (United States) (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-04-06
- DOI
- https://doi.org/10.1080/14796694.2025.2480050
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.04